Current and Emerging Pharmacotherapies for Primary CNS Lymphoma

Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin’s lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose m ethotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar t reatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL

P-164 Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future

n/

Reply to S. Zucker “The Swinging Pendulum of the Anemia of Cancer: Erythropoietin Trumps Hepcidin”

Contains fulltext : 97313.pdf (publisher's version ) (Open Access

Gastrointestinal Stromal Tumors (Gist) and Second Malignancies: a Novel 'Sentinel Tumor"?

n/

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence.

After the recent discovery of various mutations of theCALRgene,,10% of adult patients with essential thrombocythemia (ET) orprimary myelofibrosis carry no identified molecular markers.1,2More rarely, ET may occur also in children and adolescents.3Weevaluated, by Sanger sequencing, the mutation status of exon 9 oftheCALRgene in 34 ET patients younger than 20 years of age atdiagnosis (median age, 15 years; range, 1-19 years). The study wasapproved by the Institutional Ethic Committee